In clinical trials1,5,6Evidence: Large human trialsMetabolic and weight

Petrelintide1

Also called ZP83961

Key takeaway

Petrelintide, also known as ZP8396, is an experimental amylin analogue developed by Zealand Pharma with Roche, studied for weight management.1,2,3 In ZUPREME 1, a randomized, placebo-controlled Phase 2 trial in 485 adults with obesity, average weight fell by about 8% to 10% at 28 weeks with petrelintide, compared with about 2% with placebo.7 It is not FDA-approved. Phase 3 trials sponsored by Roche were recruiting in late 2026, and none of the sources reviewed here reports an approval in any country.5,6,8

Petrelintide at a glance

What it isAn investigational amylin analogue, also known as ZP8396, from Zealand Pharma and Roche.1,2,3
FDA statusNot FDA-approved. Three Phase 3 trials, including ZUPREME-4 and ZUPREME-5, are registered on ClinicalTrials.gov.5,6,8
Human evidenceOne published randomized, placebo-controlled Phase 2 trial in 485 adults, and two small randomized Phase 1 trials. A second Phase 2 trial, in type 2 diabetes, is listed as completed without results in the sources cited here.2,4,7
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is petrelintide?

Petrelintide is an experimental amylin analogue also known by its development code, ZP8396.1,2

ClinicalTrials.gov lists Zealand Pharma as the sponsor of its Phase 2 trials and Hoffmann-La Roche as the sponsor of later trials, including a combination study with Zealand Pharma as collaborator.1,3,4

How is petrelintide thought to work?

Petrelintide is designed as a long-acting analogue of amylin, a hormone involved in appetite. The ZUPREME 1 authors describe its mechanism as distinct from that of incretin-based treatments.2,7

The published trials measured its effects on body weight and side effects, but the sources reviewed here do not establish how it produces those effects in people.2,7

What do human studies show?

ZUPREME 1 randomly assigned adults with obesity, or overweight with high blood pressure or abnormal blood fats, to one of five levels of petrelintide or to placebo for 42 weeks, at 32 sites in Poland, Romania and the United States. Of 493 people randomized, 485 received treatment.7

At 28 weeks, average body weight fell by 7.9% to 9.8% across the petrelintide groups and by 1.7% with placebo. Weight kept falling to week 42, by up to 10.7%.7

Nausea was the most common side effect, in 20% of people on petrelintide and 6% on placebo. Vomiting, diarrhoea and constipation were reported at low rates in both groups, and no deaths were reported. Zealand Pharma funded the trial, and several authors are its employees.7

Earlier, two small randomized, placebo-controlled Phase 1 trials described weight reductions and no serious or severe adverse events that emerged during treatment.2

ClinicalTrials.gov also lists a Phase 1 study in people with reduced kidney function, completed as of its January 28, 2026 record. None of these trials can show long-term benefit or rule out uncommon harms, which the Phase 3 program is registered to study.5,6,9

What the evidence base contains

  • Large randomized human trial ZUPREME 1 (NCT06662539): a multicentre, randomized, double-blind, placebo-controlled Phase 2 trial in 485 adults with obesity, or overweight with high blood pressure or abnormal blood fats, without type 2 diabetes, followed for 42 weeks; the main result was weight change at 28 weeks.7
  • Controlled human trial Two randomized, blinded, placebo-controlled Phase 1 trials, one following participants for 16 weeks, in normal-weight, overweight or obese adults. The published abstract does not give total enrollment.2
  • Registered trial without results A Phase 2 trial in overweight or obesity with type 2 diabetes (NCT06926842), sponsored by Zealand Pharma and listed as completed in its September 9, 2026 registry record.4
  • Registered trial without results ZUPREME-5 (NCT07843472), ZUPREME-4 (NCT07843485) and a third Phase 3 trial in obesity or overweight (NCT07843498), sponsored by Roche and listed as recruiting in their October and November 2026 registry records.5,6,8

Evidence-strength label: Large randomized human trials. How this label is assigned

Is petrelintide FDA-approved?

No. Petrelintide remains in clinical trials. None of the sources reviewed here reports an approval of petrelintide in any country.5,6,7,8

As of their retained registry records, ZUPREME-5 (October 7, 2026), ZUPREME-4 (November 5, 2026) and a third Phase 3 trial in obesity or overweight (November 5, 2026), all sponsored by Roche, were listed as recruiting.5,6,8

A Phase 2 combination study with enicepatide, sponsored by Roche, was listed as not yet recruiting in its July 7, 2026 record.1

Timeline

  1. Results of two randomized Phase 1 trials of petrelintide are published.2
  2. ClinicalTrials.gov lists the ZUPREME Phase 2 obesity trial as completed.3
  3. ClinicalTrials.gov lists a Phase 2 trial in overweight or obesity with type 2 diabetes as completed.4
  4. Results of the ZUPREME 1 Phase 2 trial are published online in The Lancet Diabetes & Endocrinology.7
  5. The retained ClinicalTrials.gov record of the ZUPREME-5 Phase 3 trial lists it as recruiting.5
  6. The retained ClinicalTrials.gov records of ZUPREME-4 and a third Phase 3 trial list them as recruiting.6,8

What is still unknown?

What the completed Phase 2 trial in people with type 2 diabetes found: its results are not part of the sources cited here.4

Its effects and safety over longer periods and in larger groups, including people with cardiovascular disease or type 2 diabetes, which the Phase 3 trials are registered to study.5,6,8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Petrelintide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Petrelintide are the records PeptideScanner has selected and published, not every registration or paper about Petrelintide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

In clinical trials; not FDA-approved. A published randomized, placebo-controlled Phase 2 trial in 485 adults with obesity (ZUPREME 1) reported average weight reductions of about 8% to 10% at 28 weeks, against about 2% with placebo; nausea was the most common side effect. Phase 3 trials were recruiting in late 2026.↗↗↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 1.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

One selected publication reports two randomized phase 1 trials of petrelintide. This overview concerns early pharmacology, tolerability and weight observations, without a direct comparison with other weight-management medicines.↗

What the reviewed sources report

The trials reported weight reductions and predominantly mild gastrointestinal adverse events. The early-phase design and limited follow-up do not establish long-term benefit or superior tolerability to another medicine.↗

What remains unresolved?

  • What do larger, longer controlled trials establish about sustained weight changes and uncommon adverse events?↗
  • Do head-to-head trials support any comparative benefit or tolerability claim?↗

Read study designs, results, limitations, and sources →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Petrelintide?

Manually reviewed September 15, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

One selected publication reports two randomized phase 1 trials of petrelintide. This overview concerns early pharmacology, tolerability and weight observations, without a direct comparison with other weight-management medicines.1

Bottom line from this bounded source set

The trials reported weight reductions and predominantly mild gastrointestinal adverse events. The early-phase design and limited follow-up do not establish long-term benefit or superior tolerability to another medicine.1

Reviewed study record

Two early randomized trials

Design

Single- and multiple-ascending-exposure trials were randomized, blinded and placebo controlled; one part followed participants for 16 weeks.1

Population

Earlier parts enrolled normal-weight or overweight adults; the later multiple-exposure part enrolled adults with overweight or obesity. The abstract does not give total enrollment.1

Outcomes reported

The report described weight reductions and no serious or severe treatment-emergent adverse events. One participant discontinued because of gastrointestinal events.1

Limitations

The trials primarily assess early safety and pharmacology. Their size, follow-up and lack of an active comparator do not establish comparative tolerability or exclude uncommon harms.1

Reviewed source set

  1. PubMed · 42017294Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. ↗PubMed PMID 42017294 · EFetch XML reviewed 2026-09-15 · payload SHA-256 c1a7ff3f4c5ea0490055737c79808e23a6c12d28e22b288798c8e16b2d91c194
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/dom.70753. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 1

ZUPREME 1 excludes diabetes

NCT06662539 records 493 participants in a placebo-controlled phase 2 study of overweight or obesity. The eligibility criteria exclude diabetes and diabetic-range HbA1c, defining a different population from the diabetes program. NCT06662539 ↗

More findings and the sources behind them

Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.

ZUPREME 2 includes specified background diabetes treatment

NCT06926842 records 221 participants with type 2 diabetes treated with stable metformin, with or without an SGLT2 inhibitor. That background matters when interpreting glycemic or safety findings eventually reported. NCT06926842 ↗

Both primary endpoints concern weight at 28 weeks

Both records specify percentage body-weight change through week 28. This endpoint does not directly measure cardiovascular events, sustained benefit after stopping treatment, or every obesity-related complication. NCT06662539 ↗NCT06926842 ↗

The status updates are not efficacy results

Both retrieved records are marked completed, but neither includes posted summary results. ZUPREME 2 was last updated on September 9, 2026. Any effect estimate needs a separate results source rather than being inferred from completion. NCT06662539 ↗NCT06926842 ↗

What remains to be checked

  • Match ZUPREME publications or subsequent registry results to each protocol before adding effect estimates.
  • Review durability, discontinuation, gastrointestinal events and other safety findings in the diabetes and non-diabetes populations separately.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Primary reports of the named peptide administered in people, including pharmacology and secondary human-sample analyses. Reviews, modeling and preclinical reports remain indexed but are outside this human-administration subset.

7 retrieved · 1 included · 6 excluded · 0 awaiting a decision · 1 full-text appraisals

Search terms, record decisions and remaining work

"petrelintide"[Title/Abstract] OR "ZP8396"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:57:50.513416+00:00 · HTTP 200 · SHA-256 477950c3b21d4d09178b32c14cb2a7f072ccbd66d5cf34f6fe72787f6b6d2eed.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:57:51.515677+00:00 · HTTP 200 · SHA-256 8542cd3693416ffe91b436a4ac7088c9bdee4795ee6d0442459b5ddb89f209b1.

  • Eligibility decisions use titles and abstracts from the pinned PubMed results; unavailable details remain unresolved rather than inferred.
  • Full-text appraisal, study-family reconciliation, registry history and broader alias/jurisdiction searches remain separate open work.

Showing 7 of 7 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 42017294 — include: Two original randomized phase 1 human studies reported in one paper; full-text reading and study-family comparison are separate review steps. Study families: EudraCT-2021-001712-28; EudraCT-2022-001744-26.
    Structured full-text reading · PMC13243934

    This is an editorial structured reading, not a validated risk-of-bias score.

    Read the source full text (Europe PMC XML) ↗

    Randomization and masking
    Methods describe an independent unblinded randomization programmer, masked identical vials, and blinded participants and trial staff. Two trials and their cohorts are reported in one paper.
    Missing data
    Results report 133 randomized and 132 treated. All participants completed the single-exposure trial and the first multiple-exposure part; three active-group participants discontinued in the later part. Weight estimates include a post hoc repeated-measures model.
    Outcome selection
    Safety and tolerability were primary; body-weight changes were secondary. No formal sample-size calculation was performed. Registry protocols and supplementary tables have not yet been independently reconciled, so selective-reporting risk remains unresolved.
    Applicability
    One German research center enrolled otherwise healthy adults with normal weight, overweight or obesity. The later part included 48 people, all White and mostly men; observation lasted 16 weeks. No active comparator supports claims of superior tolerability.
    Funding and conflicts
    Zealand Pharma sponsored the trials and manuscript and participated in design, collection and publication. Several authors were employees or shareholders. This is a potential influence to consider, not evidence that results are false.
    Registry comparison
    The paper identifies EudraCT 2021-001712-28 and 2022-001744-26. Independent comparison of registered outcomes, amendments and supplements is still pending.

    Reviewed 2026-09-15; source SHA-256 82103b805848b3cff44466a271f84aecc0cd468cad189c04690c0593e575a7d5.

  2. PubMed 42586227 — exclude: Review of the amylin evidence base, not a new administered human study.
  3. PubMed 42452898 — exclude: Review of the amylin evidence base, not a new administered human study.
  4. PubMed 41747885 — exclude: Review of the amylin evidence base, not a new administered human study.
  5. PubMed 41344603 — exclude: Review of the amylin evidence base, not a new administered human study.
  6. PubMed 41217931 — exclude: Compound-development and preclinical potency report; the abstract describes clinical development rather than reporting a human administration trial.
  7. PubMed 40608546 — exclude: Preclinical development of a different analogue, BGM1812, not a human petrelintide administration report.

ClinicalTrials.gov search

ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.

9 retrieved · 8 included · 0 excluded · 1 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

petrelintide OR ZP8396

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:28:07.732962+00:00 · HTTP 200 · SHA-256 63c6a2842b2a24719adcbcffa8d278f6317dc0a4f6225ba886d6b7f092a4d842.

  • Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
  • Other registries and unregistered studies are outside this search.
  • Petrelintide has one ambiguous registry identity; the second trial publication linkage remains incompletely reconciled.

Showing 9 of 9 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. ClinicalTrials.gov NCT07338214 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07338214.
  2. ClinicalTrials.gov NCT05096598 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05096598.
  3. ClinicalTrials.gov NCT06926842 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06926842.
  4. ClinicalTrials.gov NCT06662539 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06662539.
  5. ClinicalTrials.gov NCT07076030 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07076030.
  6. ClinicalTrials.gov NCT05613387 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05613387.
  7. ClinicalTrials.gov NCT07589686 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07589686.
  8. ClinicalTrials.gov NCT07682818 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07682818.
  9. ClinicalTrials.gov NCT06951854 — unresolved: Autism NV01-A02 record contains a conflicting placebo name mentioning ZP8396; identity is unresolved.

FDA search

Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"PETRELINTIDE" OR products.active_ingredients.name:"ZP8396"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:54:13.566846+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Complete source-document appraisal and national European sources remain open.
    • Zero identity matches apply only to these feed fields and terms.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Complete source-document appraisal and national European sources remain open.
      • Zero identity matches apply only to these feed fields and terms.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Complete source-document appraisal and national European sources remain open.
        • Zero identity matches apply only to these feed fields and terms.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          Explore status sources, recent additions, and coverage gaps

          Living status brief

          What is the current status of Petrelintide?

          In clinical trials; not FDA-approved. A published randomized, placebo-controlled Phase 2 trial in 485 adults with obesity (ZUPREME 1) reported average weight reductions of about 8% to 10% at 28 weeks, against about 2% with placebo; nausea was the most common side effect. Phase 3 trials were recruiting in late 2026.↗↗↗↗↗

          The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

          Evidence present

          What records are connected here?

          Evidence lanes
          2
          Source years
          1
          Drugs@FDA applications
          0

          These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

          Latest source-dated record

          What changed most recently at a cited source?

          Clinical trials · source date November 16, 2026

          ClinicalTrials.gov record NCT07843472↗Added to PeptideScanner November 14, 2026

          Coverage gaps

          What remains unknown or unsupported?

          PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

          PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

          Explore the Evidence Map and record counts

          Evidence Map v1

          What kinds of records connect to Petrelintide?

          Compare collection coverage →

          This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

          12Selected dated records
          15Connected citations
          1Populated source years2026
          2/4Record lanes present

          Registered human studies

          Trial composition

          8 of 10 selected trial records include at least one phase value; 8 of 10 include a status value in the retained structured contract.

          26 public history versions connect to 4 of these trial records across 3 submitted years. Open the record-history collection →

          PhasesPhase 2 3Phase 3 3Phase 1 2
          Status at observationRecruiting 4Completed 3Not yet recruiting 1

          A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”

          A status value is unavailable here for 2 selected records; this is not counted as a trial status.

          PubMed bibliography

          Publication composition

          1 of 2 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

          Publication typesJournal Article 1

          Bibliography fields unavailable here for 1 selected record; the records remain visible as metadata observations.

          Regulatory and publication surfaces

          What is structurally connected?

          Drugs@FDA applications
          0
          FDA Federal Register documents
          0
          DailyMed SPL versions
          0
          Canonical profile
          Published
          Profile structured data
          Published
          Linked dated records
          12

          Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

          Profile publication history and record counts
          Source records by collection · 12 dated records

          Research hub

          Explore the Petrelintide evidence record

          Open all 12 records →
          12Dated records
          2Evidence types
          12Cited public sources
          1Source year

          Change ledger

          Recently changed for Petrelintide

          Open all 16 events →

          PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

          Profile updated

          Petrelintide profile

          We added the published results of the ZUPREME 1 Phase 2 trial and two more ClinicalTrials.gov records. Earlier versions said the only published human results were from Phase 1 trials.

          PeptideScanner change date
          November 16, 2026
          Evidence lane
          Profile
          Record updated

          ClinicalTrials.gov record NCT07843472

          ClinicalTrials.gov posted a newer version of NCT07843472, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

          PeptideScanner change date
          November 16, 2026
          Cited source date
          November 16, 2026
          Evidence lane
          Clinical trials
          Profile status changed

          Petrelintide profile

          We added a plain-language reader guide with cited answers, Phase 1 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 2 and Phase 3 trials.

          PeptideScanner change date
          November 14, 2026
          Evidence lane
          Profile

          Official-source collections

          Source records for Petrelintide

          Open the full research atlas →
          ClinicalTrials.gov9

          26 public history versions across these dated registry records; status labels apply only to each cited observation.

          1. NCT07843472Registry update November 16, 2026 · current at observation
          2. NCT07843485Registry update November 5, 2026 · current at observation
          3. NCT07843498Registry update November 5, 2026 · current at observation
          Explore all selected trial records →Explore all public record history →

          Evidence types

          Coverage by source year

          Selected records span January 28, 2026 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

          Continue exploring

          Profiles with overlapping source-year coverage

          Open the research atlas →

          These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

          Organizations and trial records named in cited sources

          Organizations named in cited records

          • Hoffmann-La Roche1
          • Zealand Pharma3

          Trial records

          Dated updates connected to this profile · 12

          Updates connected to this profile

          Open the full cross-source timeline →
          1. Clinical trials

            ClinicalTrials.gov record NCT07843472↗

            PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide.↗

          2. Clinical trials

            ClinicalTrials.gov record NCT07843485↗

            PeptideScanner retained ClinicalTrials.gov record NCT07843485 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was petrelintide.↗

          3. Clinical trials

            ClinicalTrials.gov record NCT07843498↗

            PeptideScanner retained ClinicalTrials.gov record NCT07843498 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was petrelintide.↗

          4. Literature metadata

            Petrelintide and the evolving role of amylin agonism in obesity.↗

            PubMed lists PMID 42810353 in The lancet. Diabetes & endocrinology as Journal Article, with publication-date metadata of 2026-09-29 (day precision). PeptideScanner associated the retained record with the identity slug petrelintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

          5. Clinical trials

            ClinicalTrials.gov record NCT06926842↗

            PeptideScanner retained ClinicalTrials.gov record NCT06926842 at 2026-09-09T19:17:17.080Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was petrelintide.↗

          6. Clinical trials

            ClinicalTrials.gov record NCT07589686↗

            PeptideScanner retained ClinicalTrials.gov record NCT07589686 at 2026-08-13T05:52:27.014Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was petrelintide.↗

          7. Literature metadata

            PubMed record PMID 42017294↗

            PeptideScanner retained PubMed bibliographic metadata for PMID 42017294 at 2026-08-10T18:13:48.775Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-04-22. PeptideScanner associated this retained record with the identity slug petrelintide. These dates describe PubMed metadata history, not the article's original publication date.↗

          8. Clinical trials

            Petrelintide combination study record posted↗

            ClinicalTrials.gov lists a Petrelintide study that is not yet recruiting sponsored by Hoffmann-La Roche.↗

          9. Clinical trials

            ClinicalTrials.gov record NCT07682818↗

            PeptideScanner retained ClinicalTrials.gov record NCT07682818 at 2026-08-10T18:10:03.938Z. Its registry update date was 2026-07-06, and PeptideScanner's reviewed identity mapping was petrelintide.↗

          10. Clinical trials

            ClinicalTrials.gov record NCT07338214↗

            PeptideScanner retained ClinicalTrials.gov record NCT07338214 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was petrelintide.↗

          11. Clinical trials

            ClinicalTrials.gov record NCT06662539↗

            PeptideScanner retained ClinicalTrials.gov record NCT06662539 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was petrelintide.↗

          12. Clinical trials

            ClinicalTrials.gov record NCT07076030↗

            PeptideScanner retained ClinicalTrials.gov record NCT07076030 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was petrelintide.↗

          Citations

          Sources

          Coverage and sources →

          Numbered markers in the text point here. Each link opens the original public record.

          1. 1
            Petrelintide With Enicepatide in Adults With Obesity or Overweight · record history version 3 · last update posted 2026-07-07 ↗

            ClinicalTrials.gov · Official source · Source checked July 22, 2026

          2. 2
            Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials (2026) · PMID 42017294 ↗

            Diabetes, Obesity and Metabolism · Official source · Source checked November 14, 2026

          3. 3
            ClinicalTrials.gov record NCT06662539 · retained source version 2026-03-23:25a9d8533efb66766440e5abf5b03342f70235dae33ae71a773e757bb8847402 ↗

            ClinicalTrials.gov · Official source · Source checked August 14, 2026

          4. 4
            ClinicalTrials.gov record NCT06926842 · retained source version 2026-09-09:66566db76c0ba35707f571957d43a26bb1a34c1cb277263d2109ca1fdebaf137 ↗

            ClinicalTrials.gov · Official source · Source checked September 9, 2026

          5. 5
            ClinicalTrials.gov record NCT07843472 · retained source version 2026-10-07:b4d7f3eecf4b6c9a8842198319f5d5c3a421bf03ca09434d4d315fdacfc97697 ↗

            ClinicalTrials.gov · Official source · Source checked November 14, 2026

          6. 6
            ClinicalTrials.gov record NCT07843485 · retained source version 2026-11-05:e5fd0540362d59efc4e0e476ab3f05c74427735d5576cee67cbafed4c6f394d5 ↗

            ClinicalTrials.gov · Official source · Source checked November 14, 2026

          7. 7
            Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial (2026) · PMID 42810355 ↗

            The Lancet Diabetes & Endocrinology · Official source · Source checked November 16, 2026

          8. 8
            ClinicalTrials.gov record NCT07843498 · retained source version 2026-11-05:9b532d149aaffed6b38bd85ef1731c2342003d62a19554586ffc692016cb1e62 ↗

            ClinicalTrials.gov · Official source · Source checked November 14, 2026

          9. 9
            ClinicalTrials.gov record NCT07076030 · retained source version 2026-01-28:68a10be352b494ee43c532b4782a5eda7e3dc609ba1c5da1829378a353712497 ↗

            ClinicalTrials.gov · Official source · Source checked September 9, 2026